摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-m-nitrobenzoyl butyric acid | 42075-28-5

中文名称
——
中文别名
——
英文名称
3-m-nitrobenzoyl butyric acid
英文别名
3-(meta-Nitrobenzoyl)buttersaeure;3-(m-Nitrobenzoyl)-buttersaeure;3-m-Nitrobenzoylbuttersaeure;3-methyl-4-(3-nitrophenyl)-4-oxobutanoic acid
3-m-nitrobenzoyl butyric acid化学式
CAS
42075-28-5
化学式
C11H11NO5
mdl
——
分子量
237.212
InChiKey
PBSHUUOWSKHHSP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    404.5±25.0 °C(Predicted)
  • 密度:
    1.337±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.4
  • 重原子数:
    17
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.27
  • 拓扑面积:
    100
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-m-nitrobenzoyl butyric acid一水合肼 作用下, 以 为溶剂, 以14.6 g的产率得到5-methyl-6-(3-nitrophenyl)-4,5-dihydro-2H-pyridazin-3-one
    参考文献:
    名称:
    Synthesis and Structure−Activity Relationships of cis-Tetrahydrophthalazinone/Pyridazinone Hybrids:  A Novel Series of Potent Dual PDE3/PDE4 Inhibitory Agents
    摘要:
    In this study, the synthesis and in vitro and in vivo pharmacological investigations of a new series of phthalazinone/pyridazinone hybrids with both PDE3 and PDE4 inhibitory activities are described. These compounds combine the pharmacophores of recently discovered 4a,5,8,8a-tetrahydro-2H-phthalazin-1-one-type inhibitors of PDE4 and the well-known 2H-pyridazin-3-one-type PDE3 inhibitors such as the tetrahydrobenzimidazoles. Most of the synthesized compounds are pharmacologically spoken PDE3/PDE4 hybrids. All hybrids show potent PDE4 inhibitory activity (pIC(50) = 7.0-8.7), whereas the pIC(50) values for inhibition of PDE3 vary from 5.4 to 7.5. In general, analogues with a 5-methyl-4,5-dihydropyridazinone moiety exhibit the highest PDE3 inhibitory activities. The highest in vivo antiinflammatory activity is displayed by phthalazinones 43 and 44 showing, at a dose of 30 mumol/kg po, 46% inhibition of arachidonic acid (AA) induced mouse ear edema. No correlation was found between the in vitro PDE3 and/or PDE4 inhibitory activity and the in vivo antiinflammatory capacity after oral dosing.
    DOI:
    10.1021/jm030776l
  • 作为产物:
    描述:
    2-溴-1-(3-硝基苯基)丙烷-1-酮盐酸 、 sodium hydride 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 10.0h, 生成 3-m-nitrobenzoyl butyric acid
    参考文献:
    名称:
    Synthesis and Structure−Activity Relationships of cis-Tetrahydrophthalazinone/Pyridazinone Hybrids:  A Novel Series of Potent Dual PDE3/PDE4 Inhibitory Agents
    摘要:
    In this study, the synthesis and in vitro and in vivo pharmacological investigations of a new series of phthalazinone/pyridazinone hybrids with both PDE3 and PDE4 inhibitory activities are described. These compounds combine the pharmacophores of recently discovered 4a,5,8,8a-tetrahydro-2H-phthalazin-1-one-type inhibitors of PDE4 and the well-known 2H-pyridazin-3-one-type PDE3 inhibitors such as the tetrahydrobenzimidazoles. Most of the synthesized compounds are pharmacologically spoken PDE3/PDE4 hybrids. All hybrids show potent PDE4 inhibitory activity (pIC(50) = 7.0-8.7), whereas the pIC(50) values for inhibition of PDE3 vary from 5.4 to 7.5. In general, analogues with a 5-methyl-4,5-dihydropyridazinone moiety exhibit the highest PDE3 inhibitory activities. The highest in vivo antiinflammatory activity is displayed by phthalazinones 43 and 44 showing, at a dose of 30 mumol/kg po, 46% inhibition of arachidonic acid (AA) induced mouse ear edema. No correlation was found between the in vitro PDE3 and/or PDE4 inhibitory activity and the in vivo antiinflammatory capacity after oral dosing.
    DOI:
    10.1021/jm030776l
点击查看最新优质反应信息

文献信息

  • 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazine hypotensive agents
    申请人:American Cyanamid Company
    公开号:US04112095A1
    公开(公告)日:1978-09-05
    This disclosure describes novel substituted 6-phenyl-1,2,4-triazolo[4,3-b]pyridazines useful as hypotensive agents.
    本公开说明了一种新型的取代的6-苯基-1,2,4-三唑并[4,3-b]吡啶嗪,可用作降压剂。
  • Method for treating anxiety in mammals
    申请人:American Cyanamid Company
    公开号:US04117130A1
    公开(公告)日:1978-09-26
    This disclosure describes compositions of matter useful as anxiolytic agents and the method of meliorating anxiety in mammals therewith; the active ingredients of said compositions of matter being certain substituted 6-phenyl-1,2,4-triazolo[4,3-b]pyridazines or the pharmacologically acceptable acid-addition salts thereof.
    本文描述了作为抗焦虑剂有用的物质组成和利用其改善哺乳动物焦虑的方法;所述物质组成的活性成分是某些取代的6-苯基-1,2,4-三唑并[4,3-b]吡啶嗪或其药理学上可接受的酸盐加成物。
  • US4092311A
    申请人:——
    公开号:US4092311A
    公开(公告)日:1978-05-30
  • US4117130A
    申请人:——
    公开号:US4117130A
    公开(公告)日:1978-09-26
  • US4112095A
    申请人:——
    公开号:US4112095A
    公开(公告)日:1978-09-05
查看更多